RIPK1 and inflammatory bowel disease: One Phase II trial of a RIPK1 inhibitor in UC has failed to demonstrate clinical efficacy (Weisel et al, 2021), but several other clinical and preclinical trials of RIPK1 inhibitors in IBD are underway.